


\*\*\*\*\* Welcome to STN International \*\*\*\*\*  
 \*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 14:07:36 ON 25 JUL 2005

=> file reg

Uploading C:\Program Files\Stnexp\Queries\10662165.str



chain nodes :

10 12 13 23

ring nodes :

1 2 3 4 5 6 7 8 9 16 17 18 19 20 21

chain bonds :

7-10 8-23 9-19 10-12 12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 16-17 16-21 17-18 18-19 19-20  
 20-21

exact/norm bonds :

1-2 1-5 2-3 3-4 7-10 8-23 10-12 12-13

exact bonds :

9-19

normalized bonds :

4-5 4-6 5-9 6-7 7-8 8-9 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :

containing 16 :

G1:C,O,S

G2:C,O,N,X

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 12:CLASS 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 23:CLASS

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S

G2 C,O,N,X

Structure attributes must be viewed using STN Express query preparation.

=&gt; s 11 sam

L2 12 SEA SSS SAM L1

=&gt; s 11 full

L3 208 SEA SSS FUL L1

=&gt; file caplus

=&gt; s 13

L4 7 L3

=&gt; s 14 and pd&lt; march 2000

20462034 PD&lt; MARCH 2000

(PD&lt;20000300)

L5 4 L4 AND PD&lt; MARCH 2000

=&gt; dis l5 1-4 bib abs hitstr

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:811252 CAPLUS

DN 132:49954

TI Thienodipyridine derivatives as antiinflammatory and antiarthritis agents

IN Sohda, Takashi; Makino, Haruhiko; Baba, Atsuo; Yamane, Taihei

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent




LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9965916	A1	19991223	WO 1999-JP3155	19990614 <--
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV,				

MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM,  
 TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2335106	AA	19991223	CA 1999-2335106	19990614 <--
AU 9940618	A1	20000105	AU 1999-40618	19990614 <--
JP 2000072776	A2	20000307	JP 1999-166365	19990614
EP 1087977	A1	20010404	EP 1999-924021	19990614
EP 1087977	B1	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 230752	E	20030115	AT 1999-924021	19990614
US 6214838	B1	20010410	US 1999-355218	19990723
PRAI JP 1998-166910	A	19980615		
WO 1999-JP3155	W	19990614		
OS MARPAT 132:49954				
GI				



AB Title compds. I [R = H, alkanoyl; X = halo; R1 = (un)substituted phenyl] were prepared. Thus, 2-cyano-4'-methoxyacetophenone (obtained from acetonitrile and 4-methoxybenzoyl chloride) reacted with 1-benzyl-4-piperidone to give a 61% yield of thienopyridine derivative II, which reacted with 1,3-dichloroacetone to give an 83% yield of thienodipyridine III; reaction of III with succinimide gave a 58% yield of the 2-(succinimidylmethyl) derivative, which underwent Pd-catalyzed debenzoylation to give I (R = H, X = Cl, R1 = 4-methoxyphenyl). This product, in a rat paw edema suppression test, showed a 94% swelling suppression rate when administered at 3.13 mg/kg once daily over 14 days.

IT 252895-78-6P 252895-79-7P 252895-88-8P


**252895-92-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(thienodipyridine derivs. as antiinflammatory and antiarthritis agents)


RN 252895-78-6 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-79-7 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-88-8 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(4-ethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-92-4 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-(4-hydroxyphenyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




IT 252895-81-1P 252895-95-7P 252895-99-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (thienodipyridine derivs. as antiinflammatory and antiarthritis agents)  
 RN 252895-81-1 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-bromo-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 252895-95-7 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-4-(3,4-dimethoxyphenyl)-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 252895-99-1 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT 199102-49-3P 252895-49-1P 252895-52-6P  
 252895-54-8P 252895-57-1P 252895-59-3P  
 252895-61-7P 252895-63-9P 252895-65-1P


252895-67-3P 252895-69-5P 252895-71-9P  
 252895-73-1P 252895-74-2P 252895-76-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(thienodipyridine derivs. as antiinflammatory and antiarthritis agents)


RN 199102-49-3 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-  
 tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl)methyl]-  
 (9CI) (CA INDEX NAME)




RN 252895-49-1 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-  
 7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl)methyl]- (9CI) (CA  
 INDEX NAME)




RN 252895-52-6 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(3-  
 methylbutoxy)phenyl]-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-  
 yl)methyl]- (9CI) (CA INDEX NAME)



RN 252895-54-8 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-bromo-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-57-1 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(4-chlorophenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-59-3 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,8-dihydro-4-[4-(trifluoromethyl)phenyl]-,

phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252895-61-7 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-[4-(1,1-dimethylethyl)phenyl]-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-63-9 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(1-methylethyl)phenyl]-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-65-1 CAPLUS  
 CN Acetamide, N-[4-[3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-4-yl]phenyl]-(9CI) (CA INDEX NAME)



RN 252895-67-3 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-4-[4-(ethoxycarbonyl)phenyl]-5,8-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252895-69-5 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-4-(4-ethoxyphenyl)-5,8-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252895-71-9 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,8-dihydro-4-[4-(2,2,2-trifluoroethoxy)phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252895-73-1 CAPLUS


CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-4-(4-ethylphenyl)-5,8-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 252895-74-2 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine-7(6H)-carboxylic acid, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,8-dihydro-4-[(4-phenylmethoxy)phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 252895-76-4 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[3-methoxy-4-(1-methylethoxy)phenyl]-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




IT **252895-91-3P 252895-97-9P 252895-98-0P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
 USES (Uses)  
 (thienodipyridine derivs. as antiinflammatory and antiarthritis agents)  
 RN 252895-91-3 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(phenylmethoxy)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 252895-97-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[3-methoxy-4-(1-methylethoxy)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 252895-98-0 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-[3-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 252895-80-0P 252895-82-2P 252895-83-3P  
252895-84-4P 252895-85-5P 252895-86-6P  
252895-87-7P 252895-89-9P 252895-90-2P


252895-93-5P 252895-94-6P 252895-96-8P  
252896-00-7P 252896-01-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thienodipyridine derivs. as antiinflammatory and antiarthritis agents)


RN 252895-80-0 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(3-methylbutoxy)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-82-2 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(4-chlorophenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-83-3 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(trifluoromethyl)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-84-4 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-[4-(1,1-dimethylethyl)phenyl]-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 252895-85-5 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(1-methylethyl)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 252895-86-6 CAPLUS


CN Acetamide, N-[4-[3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-4-yl]phenyl]- (9CI) (CA INDEX NAME)

NAME)




RN 252895-87-7 CAPLUS

CN Benzoic acid, 4-[3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 252895-89-9 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[4-(2,2,2-trifluoroethoxy)phenyl]thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 252895-90-2 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(4-ethylphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 252895-93-5 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 252895-94-6 CAPLUS  
 CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-4-(4-ethoxyphenyl)-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 252895-96-8 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 7-acetyl-3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 252896-00-7 CAPLUS


CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-2-[(2,5-dioxo-1-pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 252896-01-8 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-2-[(2,5-dioxo-1-

pyrrolidinyl)methyl]-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoroacetyl)-(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:467219 CAPLUS

DN 131:237492

TI Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b: 5,4-c']dipyridine derivatives and their anti-inflammatory effect

AU Baba, Atsuo; Mori, Akira; Yasuma, Tsuneo; Unno, Satoko; Makino, Haruhiko; Sohda, Takashi

CS Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SO Chemical & Pharmaceutical Bulletin (1999), 47(7), 993-999

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

OS CASREACT 131:237492

AB The syntheses and anti-inflammatory activities of novel thieno[2,3-b]pyridine and thieno[2,3-b: 5,4-c']dipyridine derivs. are described. These compds. were designed by modification of the quinoline template of a new type of disease-modifying antirheumatic drug (DMARD), TAK-603, and prepared by the Friedlander reaction as a key reaction. Their anti-inflammatory effects were evaluated using an adjuvant arthritis rat model. Most of the compds. which included a diethylamino moiety in the side chain had potent anti-inflammatory effect. In particular, Et 2-(diethylaminomethyl)-4-(3,4-dimethoxyphenyl)thieno[2,3-b: 5,4-c']dipyridine-3-carboxylate exhibited more potent activity than TAK-603.

IT 179327-48-1P 179327-78-7P 244298-82-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of novel thienodipyridine derivs. and their anti-inflammatory effect as disease-modifying antirheumatic drugs in relation to structure)

RN 179327-48-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2,3-

dimethyl-6-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-78-7 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 244298-82-6 CAPLUS


CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-[(3,5-dimethyl-1-piperidinyl)methyl]-5,6,7,8-tetrahydro-7-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1997:717922 CAPLUS  
 DN 128:13252  
 TI Preparation of thienodipyridinecarboxylates and analogs as drugs  
 IN Sohda, Takashi; Makino, Haruhiko; Baba, Atsuo  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 174 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9740050	A1	19971030	WO 1997-JP1413	19970423 <--
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2249029	AA	19971030	CA 1997-2249029	19970423 <--
	AU 9724053	A1	19971112	AU 1997-24053	19970423 <--
	AU 715100	B2	20000113		
	ZA 9703492	A	19971202	ZA 1997-3492	19970423 <--
	EP 900223	A1	19990310	EP 1997-919663	19970423 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1216546	A	19990512	CN 1997-193913	19970423 <--
	BR 9708738	A	20000509	BR 1997-8738	19970423
	JP 10036374	A2	19980210	JP 1997-107111	19970424 <--
	JP 10059977	A2	19980303	JP 1997-107139	19970424 <--
	US 6046189	A	20000404	US 1997-860452	19970626
	NO 9804921	A	19981222	NO 1998-4921	19981022 <--
	KR 2000010617	A	20000225	KR 1998-708515	19981023 <--
	US 6403606	B1	20020611	US 2000-506010	20000217
PRAI	JP 1996-105916	A	19960425		
	JP 1996-105917	A	19960425		
	WO 1997-JP1413	W	19970423		
	US 1997-860452	A1	19970626		
OS	MARPAT 128:13252				
GI					



AB Title compds. [I; R1 = CH2ZR; R = (un)substituted NH2 or -heterocyclyl; R2 = (esterified) CO2H or halo; R3 = (un)substituted Ph; R4R5 = Z1NR6Z2; R6 = H, hydrocarbonyl, acyl, etc.; Z = bond, O, S, (CH2)1-5, etc.; Z1,Z2 = atoms to complete a 3- to 5-membered chain] were prepared as antiinflammatories, bone resorption inhibitors, etc. Thus, 1-(4-chlorobenzoyl)-4-piperidone

was cyclocondensed with 3,4-(MeO)2C6H3COCH2CN (preparation given) and the product cyclocondensed with ClCH2CHCH2CO2Et to give I [R2 = CO2Et, R3 = C6H3(OMe)-3,4, R4R5 = CH2CH2N(COC6H4Cl-4)CH2] (II; R1 = CH2Cl) which was aminated with Et2NH to give II (R1 = CH2NEt2). Data for biol. activity of I were given.


IT 199101-52-5P 199101-66-1P 199101-67-2P  
 199101-69-4P 199101-70-7P 199101-71-8P  
 199101-72-9P 199101-73-0P 199101-75-2P  
 199101-76-3P 199101-77-4P 199101-78-5P  
 199101-79-6P 199102-00-6P 199102-04-0P  
 199102-05-1P 199102-07-3P 199102-08-4P  
 199102-10-8P 199102-11-9P 199102-13-1P  
 199102-14-2P 199102-20-0P 199102-21-1P  
 199102-26-6P 199102-27-7P 199102-28-8P  
 199102-29-9P 199102-37-9P 199102-38-0P  
 199102-39-1P 199102-40-4P 199102-41-5P  
 199102-42-6P 199102-43-7P 199102-44-8P  
 199102-45-9P 199102-46-0P 199102-47-1P  
 199102-48-2P 199102-49-3P 199102-50-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thienodipyridinecarboxylates and analogs as drugs)


RN 199101-52-5 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-(4-chlorobenzoyl)-4-(3,4-dimethoxyphenyl)-2-[[4-(ethoxycarbonyl)-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-66-1 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-b]pyridine-3,6-dicarboxylic acid, 4-(3,4-dimethoxyphenyl)-5,7-dihydro-2-(1H-1,2,4-triazol-1-ylmethyl)-, 3-ethyl 6-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199101-67-2 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-b]pyridine-3,6-dicarboxylic acid,  
4-(3,4-dimethoxyphenyl)-5,7-dihydro-2-(4H-1,2,4-triazol-4-ylmethyl)-,  
3-ethyl 6-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199101-69-4 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-benzoyl-4-(3,4-  
dimethoxyphenyl)-5,6,7,8-tetrahydro-2-(1H-1,2,4-triazol-1-ylmethyl)-,  
ethyl ester (9CI) (CA INDEX NAME)




RN 199101-70-7 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-  
5,6,7,8-tetrahydro-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 199101-71-8 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-72-9 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-benzoyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[2-(1-methyl-1H-imidazol-2-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-73-0 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-benzoyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[2-(1H-1,2,3-triazol-4-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-75-2 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyrroline-3-carboxylic acid, 7-(4-chlorobenzoyl)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[2-(1H-1,2,4-triazol-1-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-76-3 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyrroline-3-carboxylic acid, 7-(4-chlorobenzoyl)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[3-(1H-1,2,4-triazol-1-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-77-4 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-(4-chlorobenzoyl)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[4-(1H-1,2,4-triazol-1-yl)butyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199101-78-5 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-[3-(1H-1,2,4-triazol-1-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199101-79-6 CAPLUS


CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-[4-(1H-1,2,4-triazol-1-yl)butyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199102-00-6 CAPLUS


CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 7-benzoyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[(3-methyl-2,4-dioxo-1-

imidazolidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 199102-04-0 CAPLUS

CN Thieno[2,3-b:5,4-b']dipyridine-1,6(2H)-dicarboxylic acid,  
5-(3,4-dimethoxyphenyl)-3,4-dihydro-7-(1H-1,2,4-triazol-1-ylmethyl)-,  
6-ethyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199102-05-1 CAPLUS

CN Thieno[2,3-b:5,4-b']dipyridine-1,6(2H)-dicarboxylic acid,  
5-(2,3-dimethoxyphenyl)-3,4-dihydro-7-(1H-1,2,4-triazol-1-ylmethyl)-,  
6-ethyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199102-07-3 CAPLUS

CN Thieno[2,3-b:4,5-c']dipyridine-3,6(5H)-dicarboxylic acid,  
4-(3,4-dimethoxyphenyl)-7,8-dihydro-2-(1H-1,2,4-triazol-1-ylmethyl)-,  
3-ethyl 7-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199102-08-4 CAPLUS

CN Thieno[2,3-b:4,5-c']dipyridine-3,6(5H)-dicarboxylic acid,  
4-(3,4-dimethoxyphenyl)-7,8-dihydro-2-(4H-1,2,4-triazol-4-ylmethyl)-,  
3-ethyl 7-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 199102-10-8 CAPLUS

CN Thieno[2,3-b:5,4-b']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-  
5,6,7,8-tetrahydro-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 199102-11-9 CAPLUS

CN Thieno[2,3-b:4,5-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 199102-13-1 CAPLUS

CN Thieno[2,3-b:5,4-b']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 199102-14-2 CAPLUS

CN Thieno[2,3-b:4,5-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 199102-20-0 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-[(2-pyridinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 199102-21-1 CAPLUS

CN 2(1H)-Pyridinone, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 199102-26-6 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-27-7 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-(4-morpholinylmethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-28-8 CAPLUS

CN Piperazine, 1-acetyl-4-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 199102-29-9 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-37-9 CAPLUS

CN 2-Pyrrolidinone, 1-[[3-chloro-5,6,7,8-tetrahydro-4-[3-methoxy-4-(1-methylethoxy)phenyl]-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 199102-38-0 CAPLUS

CN 2-Piperidinone, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 199102-39-1 CAPLUS

CN 2H-Azepin-2-one, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]hexahydro- (9CI) (CA INDEX NAME)




RN 199102-40-4 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-41-5 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(4H-1,2,4-triazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-42-6 CAPLUS

CN 2-Pyrrolidinone, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 199102-43-7 CAPLUS

CN 2-Pyrrolidinone, 1-[[[3-chloro-5,6,7,8-tetrahydro-4-(4-hydroxy-3-methoxyphenyl)-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 199102-44-8 CAPLUS


CN 2-Pyrrolidinone, 1-[[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 199102-45-9 CAPLUS


CN 2-Pyrrolidinone, 1-[[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]-5-methyl- (9CI)

(CA INDEX NAME)




RN 199102-46-0 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine, 3-chloro-2-[[4-(4,5-dihydro-1-phenyl-1H-pyrazol-3-yl)oxy]methyl]-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 199102-47-1 CAPLUS

CN 3-Pyrazolidinone, 2-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 199102-48-2 CAPLUS

CN 3H-Pyrazol-3-one, 2-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]-2,4-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 199102-49-3 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 199102-50-6 CAPLUS


CN 2-Pyrrolidinone, 1-[[3-chloro-4-(3,4-dimethoxyphenyl)thieno[2,3-b:5,4-c']dipyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1996:466919 CAPLUS

DN 125:114583  
 TI Thienopyridine or thienopyrimidine derivatives and their use  
 IN Sohda, Takashi; Makino, Haruhiko; Baba, Atsuo  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614319	A1	19960517	WO 1995-JP2271	19951107 <--
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202985	AA	19960517	CA 1995-2202985	19951107 <--
	AU 9538158	A1	19960531	AU 1995-38158	19951107 <--
	AU 699354	B2	19981203		
	EP 791000	A1	19970827	EP 1995-936112	19951107 <--
	EP 791000	B1	20021002		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1162958	A	19971022	CN 1995-196119	19951107 <--
	HU 77348	A2	19980330	HU 1997-2020	19951107 <--
	AT 225351	E	20021015	AT 1995-936112	19951107
	JP 08225577	A2	19960903	JP 1995-290204	19951108 <--
	US 5747486	A	19980505	US 1995-571915	19951227 <--
	NO 9702043	A	19970625	NO 1997-2043	19970502 <--
	FI 9701974	A	19970618	FI 1997-1974	19970507 <--
PRAI	JP 1994-273801	A	19941108		
	JP 1994-320055	A	19941222		
	WO 1995-JP2271	W	19951107		
OS	MARPAT 125:114583				
GI					



AB This invention provides anti-inflammatory agents, particularly agents for treating arthritis, and bone resorption inhibiting agents containing a thienopyridine derivative I (R = Et2N, triazolyl, imidazolyl, pyrrolidinyl, piperidino, morpholino, etc.; R1 = Ph, di- and trimethoxyphenyl; R2 = R3 = Me, R2R3 = CH2SCH2CH2, CH2NR4CH2CH2, R4 = Me, Et, Pr, benzyl, etc.).

IT 179327-48-1P 179327-49-2P 179327-57-2P  
 179327-62-9P 179327-63-0P 179327-67-4P  
 179327-68-5P 179327-76-5P 179327-77-6P  
 179327-78-7P 179327-79-8P 179327-80-1P

179327-81-2P 179327-86-7P 179327-87-8P


179327-88-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of antiinflammatory, antiarthritic and antiosteoporitic thienopyrimidines)


RN 179327-48-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-49-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2,3-dimethyl-6-(4H-1,2,4-triazol-4-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-57-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(3,4-dimethoxyphenyl)-2,3-dimethyl-6-[[[1-methyl-1H-imidazol-2-yl]thio]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-62-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(4-chlorophenyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-63-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-(4-chlorophenyl)-2,3-dimethyl-6-(4H-1,2,4-triazol-4-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-67-4 CAPLUS

CN 6H-Thiopyrano[4',3':4,5]thieno[2,3-b]pyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,8-dihydro-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-68-5 CAPLUS

CN 6H-Thiopyrano[4',3':4,5]thieno[2,3-b]pyridine-3-carboxylic acid,  
4-(3,4-dimethoxyphenyl)-5,8-dihydro-2-(4H-1,2,4-triazol-4-ylmethyl)-,  
ethyl ester (9CI) (CA INDEX NAME)




RN 179327-76-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-[4-methoxy-3-(1-  
methylethoxy)phenyl]-2,3-dimethyl-6-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl  
ester (9CI) (CA INDEX NAME)




RN 179327-77-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxylic acid, 4-[4-methoxy-3-(1-  
methylethoxy)phenyl]-2,3-dimethyl-6-(4H-1,2,4-triazol-4-ylmethyl)-, ethyl  
ester (9CI) (CA INDEX NAME)




RN 179327-78-7 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-79-8 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-7-(phenylmethyl)-2-(4H-1,2,4-triazol-4-ylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-80-1 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,5-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-(1H-imidazol-1-ylmethyl)-7-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-81-2 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,5-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[[1-methyl-1H-imidazol-2-yl]thio]methyl]-7-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-86-7 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-2-[(4-methoxyphenyl)methyl]-2-(1-pyrrolidinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 179327-87-8 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 5,6,7,8-tetrahydro-2-(4-morpholinylmethyl)-4-phenyl-7-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 179327-88-9 CAPLUS

CN Thieno[2,3-b:5,4-c']dipyridine-3-carboxylic acid, 5,6,7,8-tetrahydro-4-phenyl-7-(phenylmethyl)-2-(1-piperidinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



=> s 14 not 15

L6 3 L4 NOT L5

=> dis 16 1-3 bib abs

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:173611 CAPLUS

DN 138:221576

TI Process for preparation of thienopyridine derivatives as antiinflammatory agents

IN Tawada, Hiroyuki; Nagata, Toshiaki; Tanaka, Takahiro; Hanaoka, Tadashi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018590	A1	20030306	WO 2002-JP8445	20020822
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

JP 2003137889 A2 20030514 JP 2002-241876 20020822  
 PRAI JP 2001-254598 A 20010824  
 OS MARPAT 138:221576  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB This invention pertains to prepn method of thienopyridine derivs. I and II [wherein G = halo, OH, (un)substituted amino, alkyl, or alkoxy; X = (un)substituted alkylenyl; n = 2-4; ring A = (un)substituted Ph; ring B = (un)substituted 5-8 membered ring without a nitrogen atom] and salts thereof. For example, compound III was prepared in a multi-step synthesis comprising a ring closure reaction in good yield. I are useful as antiinflammatory agents for inhibition of bone resorption and production of cytokine (do data). Formulations containing I as an active ingredient were also described.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:661430 CAPLUS

DN 135:226889

TI Preparation of thienopyridines as antiinflammatory agents

IN Yasuma, Tsuneo; Baba, Atsuo; Makino, Haruhiko; Aoki, Isao; Nagata, Toshiaki

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064685	A2	20010907	WO 2001-JP1483	20010228
	WO 2001064685	A3	20020808		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 591031	B	20040611	TW 2001-90103874	20010221
	CA 2397165	AA	20010907	CA 2001-2397165	20010228
	AU 2001035985	A5	20010912	AU 2001-35985	20010228
	JP 2001316390	A2	20011113	JP 2001-54421	20010228
	EP 1259515	A2	20021127	EP 2001-908123	20010228
	EP 1259515	B1	20041110		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008840	A	20021217	BR 2001-8840	20010228
	NZ 520155	A	20030630	NZ 2001-520155	20010228
	AT 282042	E	20041115	AT 2001-908123	20010228

ES 2227139	T3	20050401	ES 2001-1908123	20010228
ZA 2002005145	A	20030904	ZA 2002-5145	20020626
US 2003130517	A1	20030710	US 2002-204593	20020822
US 6653476	B2	20031125		
NO 2002004107	A	20020927	NO 2002-4107	20020828
HK 1048120	A1	20050506	HK 2003-100300	20030113
US 2004054183	A1	20040318	US 2003-662165	20030903
PRAI JP 2000-105770	A	20000229		
WO 2001-JP1483	W	20010228		
US 2002-204593	A3	20020822		
OS MARPAT 135:226889				
GI				



I



II

AB The title compds. [I; G = halo, OH, (un)substituted NH<sub>2</sub>, etc.; alk = alkylene; X = O, (un)oxidized S, (CH<sub>2</sub>)<sub>q</sub> (q = 0-5); R = (un)substituted NH<sub>2</sub>, (un)substituted heterocyclyl; B = (un)substituted Y-containing 5-8 membered ring (no N atom in the ring); Y = O, (un)oxidized S, C(:S), etc.; A = (un)substituted Ph], useful as anti-inflammatory drugs, particularly as remedies for arthritis, were prepared and formulated. E.g., a 3-step synthesis of II was given. The compds. I exhibited efficacy in suppressing the footpad swelling in rats (data given).

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:209911 CAPLUS

DN 132:241976

TI Sustained-release oral preparations containing anti-inflammatory antirheumatic compounds

IN Okochi, Kazuhiro; Shimizu, Toshihiro

PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 60 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000016776	A1	20000330	WO 1999-JP5046	19990916
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9956521	A1	20000410	AU 1999-56521	19990916
	JP 2000154137	A2	20000606	JP 1999-263051	19990917
PRAI	JP 1998-265234	A	19980918		
	WO 1999-JP5046	W	19990916		

OS MARPAT 132:241976

AB Oral preps. with sustained release are prepared by mixing (1) a quinoline or quinazoline derivative or a thienopyridine or thienopyrimidine derivative with

(2) a gelling substance optionally together with (3) a disintegration aid. The active ingredients have anti-inflammatory or anti-rheumatic activities. A mixture containing Et 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate 400 g, hydroxypropyl Me cellulose 324 g, and erythritol 40 g was granulated. The obtained granules 600 g were blended with crystalline cellulose 15 g, silica 6 g, and Mg stearate 6 g, then tableted (429 mg/each).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.95	192.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

STN INTERNATIONAL LOGOFF AT 14:10:07 ON 25 JUL 2005

10/662,165



R = Het

X = O / S(CH<sub>2</sub>)<sub>g</sub><sup>0-5</sup>

G = Ad / O / N / AK

Ans 4/4

WO 96/14319

85 pages

y = S

X = (CH<sub>2</sub>)<sub>g</sub> ⇒ g = 0

Het ⇒ triazole

67 C<sup>10</sup>

US 747 686

Reference A3